Structural Basis for Catalytic and Inhibitory Mechanisms of Human Prostaglandin Reductase PTGR2

Structure

Volumn 16, Issue 11, 2008, Pages 1714-1723

  Wu, Yu Hauh ^a   Ko, Tzu Ping ^a,b   Guo, Rey Ting ^a   Hu, Su Ming ^a   Chuang, Lee Ming ^c   Wang, Andrew H J ^a,b  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

PROTEINS

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN E2; INDOMETACIN; NICOTINAMIDE; PROLINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN INHIBITOR; PTGR2 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CATALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME KINETICS; ENZYME SUBSTRATE; MUTAGENESIS; MUTATIONAL ANALYSIS; PLASTICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REACTION ANALYSIS; X RAY DIFFRACTION;

ALCOHOL DEHYDROGENASE; AMINO ACID SEQUENCE; ANIMALS; CATALYSIS; DINOPROSTONE; GUINEA PIGS; HUMANS; INDOMETHACIN; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; NIACINAMIDE; PROTEIN BINDING; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 55249106494     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2008.09.007     Document Type: Article

References (37)

1. Airenne T.T., Torkko J.M., Van den Plas S., Sormunen R.T., Kastaniotis A.J., Wierenga R.K., and Hiltunen J.K. Structure-function analysis of enoyl thioester reductase involved in mitochondrial maintenance. J. Mol. Biol. 327 (2003) 47-59
2. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
3. Chen Z.J., Pudas R., Sharma S., Smart O.S., Juffer A.H., Hiltunen J.K., Wierenga R.K., and Haapalainen A.M. Structural enzymological studies of 2-enoyl thioester reductase of the human mitochondrial FAS II pathway: new insights into its substrate recognition properties. J. Mol. Biol. 379 (2008) 830-844
4. Chou W.L., Chuang L.M., Chou C.C., Wang A.H., Lawson J.A., FitzGerald G.A., and Chang Z.F. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor γ activation. J. Biol. Chem. 282 (2007) 18162-18172
5. Duax W.L., Griffin J.F., and Ghosh D. The fascinating complexities of steroid-binding enzymes. Curr. Opin. Struct. Biol. 6 (1996) 813-823
6. Duax W.L., Pletnev V., Addlagatta A., Bruenn J., and Weeks C.M. Rational proteomics I. Fingerprint identification and cofactor specificity in the short-chain oxidoreductase (SCOR) enzyme family. Proteins 53 (2003) 931-943
7. Edwards K.J., Barton J.D., Rossjohn J., Thorn J.M., Taylor G.L., and Ollis D.L. Structural and sequence comparisons of quinone oxidoreductase, ζ-crystallin, and glucose and alcohol dehydrogenases. Arch. Biochem. Biophys. 328 (1996) 173-183
8. Ensor C.M., Zhang H., and Tai H.H. Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J. 330 (1998) 103-108
9. Hansen H.S. Purification and assay of 15-ketoprostaglandin δ 13-reductase from bovine lung. Methods Enzymol. 86 (1982) 156-163
10. Hori T., Yokomizo T., Ago H., Sugahara M., Ueno G., Yamamoto M., Kumasaka T., Shimizu T., and Miyano M. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J. Biol. Chem. 279 (2004) 22615-22623
11. Hori T., Ishijima J., Yokomizo T., Ago H., Shimizu T., and Miyano M. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. J. Biochem. 140 (2006) 457-466
12. Hull M.A., Gardner S.H., and Hawcroft G. Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat. Rev. 29 (2003) 309-320
13. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002) 360-372
14. Jiang C., Ting A.T., and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
15. Jornvall H., Persson B., and Jeffery J. Characteristics of alcohol/polyol dehydrogenases. The zinc-containing long-chain alcohol dehydrogenases. Eur. J. Biochem. 167 (1987) 195-201
16. Knight D.M., Chapman A.B., Navre M., Drinkwater L., Bruno J.J., and Ringold G.M. Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin. Mol. Endocrinol. 1 (1987) 36-43
17. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
18. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 270 (1995) 12953-12956
19. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
20. Levin I., Schwarzenbacher R., McMullan D., Abdubek P., Ambing E., Biorac T., Cambell J., Canaves J.M., Chiu H.J., Dai X., et al. Crystal structure of a putative NADPH-dependent oxidoreductase (GI: 18204011) from mouse at 2.10 Å resolution. Proteins 56 (2004) 629-633
21. Lovering A.L., Ride J.P., Bunce C.M., Desmond J.C., Cummings S.M., and White S.A. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 64 (2004) 1802-1810
22. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125 (1999) 156-165
23. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
24. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology, Volume 276, Macromolecular Crystallography, Part A (1997), Academic Press, New York 307-326
25. Quidville V., Segond N., Pidoux E., Cohen R., Jullienne A., and Lausson S. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 145 (2004) 2561-2571
26. Riveros-Rosas H., Julian-Sanchez A., Villalobos-Molina R., Pardo J.P., and Pina E. Diversity, taxonomy and evolution of medium-chain dehydrogenase/reductase superfamily. Eur. J. Biochem. 270 (2003) 3309-3334
27. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., and Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4 (1998) 1046-1052
28. Shiraki T., Kamiya N., Shiki S., Kodama T.S., Kakizuka A., and Jingami H. α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J. Biol. Chem. 280 (2005) 14145-14153
29. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56 (2004) 387-437
30. Tai H.H., Ensor C.M., Tong M., Zhou H., and Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68-69 (2002) 483-493
31. Thorn J.M., Barton J.D., Dixon N.E., Ollis D.L., and Edwards K.J. Crystal structure of Escherichia coli QOR quinone oxidoreductase complexed with NADPH. J. Mol. Biol. 249 (1995) 785-799
32. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
33. Wierenga R.K., and Hol W.G. Predicted nucleotide-binding properties of p21 protein and its cancer-associated variant. Nature 302 (1983) 842-844
34. Williams I.H., and Polakis S.E. Differentiation of 3T3-L1 fibroblasts to adipocytes. The effect of indomethacin, prostaglandin E1 and cyclic AMP on the process of differentiation. Biochem. Biophys. Res. Commun. 77 (1977) 175-186
35. Yamada T., Komoto J., Watanabe K., Ohmiya Y., and Takusagawa F. Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2). J. Mol. Biol. 348 (2005) 1163-1176
36. Youn B., Kim S.J., Moinuddin S.G., Lee C., Bedgar D.L., Harper A.R., Davin L.B., Lewis N.G., and Kang C. Mechanistic and structural studies of apoform, binary, and ternary complexes of the Arabidopsis alkenal double bond reductase At5g16970. J. Biol. Chem. 281 (2006) 40076-40088
37. Zhang X., Morham S.G., Langenbach R., and Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190 (1999) 451-459